Sanjivani Paranteral Ltd
Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]
- Market Cap ₹ 280 Cr.
- Current Price ₹ 236
- High / Low ₹ 397 / 168
- Stock P/E 34.6
- Book Value ₹ 32.0
- Dividend Yield 0.00 %
- ROCE 30.2 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 46.4% CAGR over last 5 years
Cons
- Stock is trading at 7.37 times its book value
- Promoter holding is low: 28.9%
- Debtor days have increased from 44.5 to 86.8 days.
- Working capital days have increased from 1.43 days to 85.5 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
158.50 | 133.03 | 115.31 | 32.53 | 17.96 | 25.09 | 16.29 | 25.09 | 30.59 | 41.45 | 58.95 | 70.10 | |
148.93 | 127.71 | 120.84 | 55.81 | 70.17 | 26.85 | 16.62 | 22.95 | 24.86 | 35.80 | 50.72 | 59.74 | |
Operating Profit | 9.57 | 5.32 | -5.53 | -23.28 | -52.21 | -1.76 | -0.33 | 2.14 | 5.73 | 5.65 | 8.23 | 10.36 |
OPM % | 6.04% | 4.00% | -4.80% | -71.56% | -290.70% | -7.01% | -2.03% | 8.53% | 18.73% | 13.63% | 13.96% | 14.78% |
2.51 | 1.24 | 0.73 | 2.85 | 0.48 | 0.96 | 0.25 | 0.26 | 0.24 | 0.54 | 0.52 | 1.21 | |
Interest | 8.09 | 7.92 | 8.81 | 4.79 | 0.45 | 0.33 | 0.66 | 0.13 | 0.21 | 0.36 | 0.25 | 0.59 |
Depreciation | 0.95 | 1.41 | 1.36 | 1.20 | 1.19 | 1.17 | 1.07 | 0.86 | 0.88 | 0.89 | 0.93 | 0.62 |
Profit before tax | 3.04 | -2.77 | -14.97 | -26.42 | -53.37 | -2.30 | -1.81 | 1.41 | 4.88 | 4.94 | 7.57 | 10.36 |
Tax % | 47.37% | -13.00% | -2.20% | -0.72% | -0.60% | -10.00% | -5.52% | -0.71% | 0.61% | 8.70% | 18.63% | 21.81% |
1.59 | -2.41 | -14.64 | -26.22 | -53.06 | -2.07 | -1.71 | 1.42 | 4.85 | 4.51 | 6.17 | 8.10 | |
EPS in Rs | 2.70 | -4.09 | -24.82 | -44.45 | -89.96 | -3.51 | -2.90 | 1.67 | 4.85 | 4.51 | 5.28 | 6.82 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7.33% |
Compounded Sales Growth | |
---|---|
10 Years: | -6% |
5 Years: | 34% |
3 Years: | 32% |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | 19% |
5 Years: | 46% |
3 Years: | 19% |
TTM: | 31% |
Stock Price CAGR | |
---|---|
10 Years: | 31% |
5 Years: | 103% |
3 Years: | 65% |
1 Year: | 35% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 25% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 8.50 | 10.00 | 10.00 | 11.68 | 11.88 |
Reserves | 29.11 | 26.24 | 11.60 | -14.62 | -58.72 | -53.10 | -54.81 | -53.39 | -17.58 | -13.07 | 16.22 | 26.12 |
56.90 | 57.06 | 62.20 | 59.89 | 48.23 | 48.09 | 48.91 | 46.05 | 6.00 | 2.49 | 0.97 | 5.63 | |
25.46 | 24.48 | 13.42 | 9.15 | 29.61 | 17.09 | 15.66 | 18.11 | 19.87 | 21.59 | 14.53 | 21.37 | |
Total Liabilities | 117.37 | 113.68 | 93.12 | 60.32 | 25.02 | 17.98 | 15.66 | 19.27 | 18.29 | 21.01 | 43.40 | 65.00 |
24.24 | 13.52 | 12.69 | 11.19 | 10.17 | 8.99 | 8.04 | 7.62 | 7.42 | 7.57 | 9.94 | 20.56 | |
CWIP | 0.07 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 3.00 |
93.01 | 100.10 | 80.38 | 49.08 | 14.80 | 8.94 | 7.57 | 11.60 | 10.82 | 13.39 | 33.46 | 41.44 | |
Total Assets | 117.37 | 113.68 | 93.12 | 60.32 | 25.02 | 17.98 | 15.66 | 19.27 | 18.29 | 21.01 | 43.40 | 65.00 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8.77 | -1.20 | 0.45 | 9.57 | 3.05 | 2.48 | -0.17 | 0.58 | 8.52 | 4.68 | -10.70 | -0.24 | |
-1.32 | 8.68 | -0.50 | 0.30 | -0.20 | 0.02 | -0.12 | -0.42 | -0.67 | -0.99 | -12.21 | -5.81 | |
-7.57 | -7.30 | -0.51 | -10.05 | -2.83 | -2.30 | 0.33 | -0.26 | -7.68 | -3.73 | 23.16 | 6.14 | |
Net Cash Flow | -0.12 | 0.18 | -0.57 | -0.18 | 0.03 | 0.20 | 0.03 | -0.09 | 0.17 | -0.04 | 0.24 | 0.09 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 149.34 | 184.24 | 151.59 | 358.38 | 107.71 | 75.79 | 23.97 | 96.45 | 58.71 | 17.52 | 29.10 | 86.85 |
Inventory Days | 54.73 | 68.59 | 65.35 | 127.41 | 34.08 | 13.56 | 66.80 | 22.43 | 51.89 | 105.21 | 124.70 | 93.96 |
Days Payable | 48.78 | 37.50 | 19.51 | 42.51 | 169.13 | 292.82 | 434.62 | 261.00 | 339.20 | 269.82 | 73.56 | 137.51 |
Cash Conversion Cycle | 155.29 | 215.34 | 197.43 | 443.28 | -27.33 | -203.47 | -343.84 | -142.12 | -228.61 | -147.08 | 80.24 | 43.30 |
Working Capital Days | 144.80 | 198.43 | 180.87 | 368.14 | -460.72 | -181.99 | -342.37 | -174.86 | -134.24 | -114.03 | 32.82 | 85.50 |
ROCE % | 12.18% | 5.95% | -7.31% | -35.52% | -227.18% | -258.43% | 265.52% | 55.28% | 30.21% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
30 May - Transcript of Earning call for the year and quarter ended 31st March 2025
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report submitted for FY ended 31 March 2025.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 28 May
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
28 May - Audio recording of Q4 and FY25 earnings call made available online.
- Announcement under Regulation 30 (LODR)-Investor Presentation 27 May
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jul 2024TranscriptNotesPPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
Business Overview:[1][2]
SPL is a WHO-GMP, DIGEMID, and DDA-certified pharmaceutical company specializing in high-quality parenteral and oral solid formulations. It serves key therapeutic areas including CNS, CVS, antibiotics, urology, anesthetics, gastroenterology, anti-diabetics, anti-fungals, anti-depressants, anti-allergics, muscle relaxants, and vitamin supplements.